PNT · Point Biopharma Global Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $9.46M | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $26.91M | $31.28M | $26.91M | - | $20.80M | $20.81M | $4.27M | - | $13.00M | $2.16M |
| SG&A | $5.51M | $5.09M | $5.01M | - | $3.84M | $4.08M | $3.81M | - | $4.03M | $1.95M |
| Total Operating Expenses | $32.42M | $36.36M | $31.92M | - | $24.64M | $24.89M | $16.31M | - | $17.03M | $3.23M |
| D&A | - | - | $537.6K | - | - | - | $224.2K | - | - | - |
| Operating Income | ($29.63M) | ($31.50M) | ($22.46M) | - | ($24.64M) | ($24.89M) | ($16.31M) | - | ($17.03M) | ($8.65M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $871.4K | ($921.3K) | ($238.6K) | - | $180.5K | $183.4K | $40.4K | - | $81.0K | $123.8K |
| Net Income | ($24.77M) | ($25.41M) | ($16.53M) | - | ($24.01M) | ($24.58M) | ($16.38M) | - | ($17.12M) | ($1.58M) |
| EPS - Basic | ($0.23) | ($0.24) | ($0.16) | - | ($0.26) | ($0.15) | ($0.18) | - | ($0.19) | - |
| EPS - Diluted | ($0.23) | ($0.24) | ($0.16) | - | ($0.26) | ($0.15) | ($0.10) | - | ($0.06) | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.61M | $57.29M | $111.14M | $286.43M | $125.78M | $78.11M | $227.39M | $238.82M | $252.83M | $273.74M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.89M | $13.90M | $15.92M | $7.70M | $3.20M | $8.07M | $6.12M | $1.74M | $3.22M | $5.02M |
| Current Assets | $353.25M | $432.38M | $434.58M | $530.82M | $296.23M | $204.91M | $232.61M | $243.85M | $259.29M | $281.81M |
| Total Assets | $477.70M | $497.77M | $558.52M | $578.32M | $325.69M | $234.24M | $252.98M | $263.26M | $277.20M | $297.46M |
| Current Liabilities | $38.67M | $41.16M | $77.85M | $79.74M | $16.61M | $18.80M | $13.64M | $7.98M | $8.09M | $11.91M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $53.51M | $50.32M | $86.74M | $91.37M | $16.61M | $18.86M | $13.71M | $8.05M | $8.16M | $11.97M |
| Stockholders' Equity | $424.19M | $447.45M | $471.78M | $486.95M | $309.08M | $215.38M | $239.27M | $255.21M | $269.04M | $7.68M |
| Retained Earnings | ($27.71M) | ($2.93M) | $22.48M | $39.01M | ($124.26M) | ($100.25M) | ($75.67M) | ($59.28M) | ($45.09M) | ($27.97M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($22.39M) | - | - | - | ($10.49M) | - | - | - |
| Investing Cash Flow | - | - | ($153.04M) | - | - | - | ($186.8K) | - | - | - |
| Financing Cash Flow | - | - | $145.9K | - | - | - | $942 | - | - | - |
| CapEx | - | - | $3.52M | - | - | - | $940.9K | - | - | - |
| Free Cash Flow | - | - | ($25.92M) | - | - | - | ($11.43M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -237.5% | - | - | - | - | - | - | - |
| EBITDA margin | - | - | -231.8% | - | - | - | - | - | - | - |
| Net margin | - | - | -174.8% | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | -274.0% | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 1.57 | - | - | - | 0.70 | - | - | - |
| R&D / Revenue | - | - | 284.5% | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | 53.0% | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.2% | -5.1% | -3.0% | - | -7.4% | -10.5% | -6.5% | - | -6.2% | -0.5% |
| Return on equity | -5.8% | -5.7% | -3.5% | - | -7.8% | -11.4% | -6.8% | - | -6.4% | -20.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 9.14 | 10.51 | 5.58 | 6.66 | 17.84 | 10.90 | 17.05 | 30.56 | 32.03 | 23.66 |
| Quick ratio | 9.14 | 10.51 | 5.58 | 6.66 | 17.84 | 10.90 | 17.05 | 30.56 | 32.03 | 23.66 |
| Cash ratio | 0.56 | 1.39 | 1.43 | 3.59 | 7.57 | 4.16 | 16.67 | 29.93 | 31.24 | 22.98 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.13 | 1.11 | 1.18 | 1.19 | 1.05 | 1.09 | 1.06 | 1.03 | 1.03 | 38.71 |
| Liabilities / Assets | 0.11 | 0.10 | 0.16 | 0.16 | 0.05 | 0.08 | 0.05 | 0.03 | 0.03 | 0.04 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.02 | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -20.3% | -26.5% | -37.7% | - | -44.7% | -187.8% | -1062.9% | - | -10018.8% | - |
| Net income growth (YoY) | -3.2% | -3.4% | -0.9% | - | -40.3% | -1452.9% | -1070.8% | - | -10252.4% | -8072.0% |
| EPS growth (YoY) | 11.5% | -60.0% | -60.0% | - | -333.3% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -126.7% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 37.2% | 107.7% | 97.2% | 90.8% | 14.9% | 2702.7% | 4685.5% | 5004.3% | 5280.8% | 136372.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing POINT Biopharma Global Inc. against the 5 most active filers in the same SIC group.